18
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Exploring the relationship between polio type 2 serum neutralizing antibodies and intestinal immunity using data from two randomized controlled trials of new bOPV-IPV immunization schedules

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • Bivalent Oral Polio Vaccine (bOPV) without type 2 poliovirus has replaced trivalent OPV globally.

          • Inactivated polio vaccine is now the only elective source of protection against type 2 poliovirus.

          • We examined the relationship of humoral and intestinal type 2 immunity from new IPV-bOPV schedules.

          • High neutralizing antibody titers were weakly associated with lower type 2 shedding.

          Abstract

          Background

          Inactivated polio vaccine (IPV) is now the only source of routine type 2 protection. The relationship, if any, between vaccine-induced type 2 humoral and intestinal immunity is poorly understood.

          Methods

          Two clinical trials in five Latin American countries of mixed or sequential bOPV-IPV schedules in 1640 infants provided data on serum neutralizing antibodies (NAb) and intestinal immunity, assessed as viral shedding following oral mOPV2 challenge. Analyses with generalized additive and quantile regression models examined the relationships between prechallenge NAb titers and proportion, duration and titers (magnitude) of viral shedding.

          Results

          We found a statistically significant (p < .0001) but weak relationship between NAb titer at the time of mOPV2 challenge and the Shedding Index Endpoint, the mean log 10 stool viral titer over 4 post-challenge assessments. Day 28 post-challenge shedding was 13.4% (8.1%, 18.8%) lower and the Day 21 post-challenge median titer of shed virus was 3.10 log 10 (2.21, 3.98) lower for subjects with NAb titers at the ULOQ as compared with LLOQ on day of challenge. Overall, there was a weak but significant negative relationship, with high NAb titers associated with lower rates of viral shedding, an effect supported by subset analysis to elucidate between-country differences.

          Conclusions

          Taken alone, the weak association between pre-challenge NAb titers following IPV or mixed/sequential bOPV/IPV immunization and differences in intestinal immunity is insufficient to predict polio type 2 intestinal immunity; even very high titers may not preclude viral shedding. Further research is needed to identify predictive markers of intestinal immunity in the context of global OPV cessation and IPV-only immunization.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: not found
          • Book Chapter: not found

          A New Look at the Statistical Model Identification

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Vaccines: correlates of vaccine-induced immunity.

            The immune system is redundant, and B and T cells collaborate. However, almost all current vaccines work through induction of antibodies in serum or on mucosa that block infection or interfere with microbial invasion of the bloodstream. To protect, antibodies must be functional in the sense of neutralization or opsonophagocytosis. Correlates of protection after vaccination are sometimes absolute quantities but often are relative, such that most infections are prevented at a particular level of response but some will occur above that level because of a large challenge dose or deficient host factors. There may be >1 correlate of protection for a disease, which we term "cocorrelates." Either effector or central memory may correlate with protection. Cell-mediated immunity also may operate as a correlate or cocorrelate of protection against disease, rather than against infection. In situations where the true correlate of protection is unknown or difficult to measure, surrogate tests (usually antibody measurements) must suffice as predictors of protection by vaccines. Examples of each circumstance are given.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Goodness of Fit and Related Inference Processes for Quantile Regression

                Bookmark

                Author and article information

                Contributors
                Journal
                Vaccine
                Vaccine
                Vaccine
                Elsevier Science
                0264-410X
                1873-2518
                19 December 2017
                19 December 2017
                : 35
                : 52
                : 7283-7291
                Affiliations
                [a ]Bill & Melinda Gates Foundation, Seattle, WA, USA
                [b ]Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
                [c ]Center for Global Health and Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA
                [d ]Millennium Institute of Immunology and Immunotherapy, Faculty of Medicine, University of Chile, Santiago, Chile
                [e ]Centers for Disease Control and Prevention, Atlanta, GA, USA
                [f ]Global Research in Infectious Diseases (GRID), Rio de Janeiro, Brazil
                [g ]Fighting Infectious Diseases in Emerging Countries (FIDEC), Miami, FL, USA
                [h ]Fred Hutchinson Cancer Research Center, Seattle, WA, USA
                Author notes
                [* ]Corresponding author at: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA.Vaccine and Infectious Disease DivisionFred Hutchinson Cancer Research Center1100 Fairview Ave NSeattleWA98109USA chris@ 123456gastsc.com
                Article
                S0264-410X(17)31548-7
                10.1016/j.vaccine.2017.11.006
                5725506
                29150209
                8e9fa2bb-9541-49c0-9525-8f0e53dce2e2
                © 2017 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 17 May 2017
                : 18 July 2017
                : 3 November 2017
                Categories
                Article

                Infectious disease & Microbiology
                poliovirus,vaccination,humoral immunity,intestinal immunity,endgame

                Comments

                Comment on this article